3 dated clinical items. Most recent: Oral GLP-1 readouts land below injectable tirzepatide on effect size (2026-05-01).
Clinical items are the slowest-moving and the most load-bearing. Trial results decide what any of this is for.
Why clinical developments matter here
We report the primary endpoint, the population and the timepoint, because those three determine what a figure supports. A number quoted without them is decoration.
Where a result reframes practice rather than confirming it — the withdrawal evidence, the head-to-head — we say what it changes about cost and duration, since that is the part patients act on.
All clinical items
Oral GLP-1 readouts land below injectable tirzepatide on effect size
Convenience and price improve; magnitude does not match the injectable…
SURMOUNT-5 puts tirzepatide 20.2% against semaglutide 13.7%
The only randomised head-to-head between the two molecules, and the number every comparison…
Withdrawal data reframe tirzepatide as maintenance therapy, not a course
Participants moved to placebo regained substantially; those who continued held or kept…
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.